Aclarion, Inc., (ACON): Price and Financial Metrics


Aclarion, Inc., (ACON): $0.72

0.11 (+17.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACON Stock Price Chart Interactive Chart >

Price chart for ACON

ACON Price/Volume Stats

Current price $0.72 52-week high $4.05
Prev. close $0.61 52-week low $0.56
Day low $0.62 Volume 86,812
Day high $0.74 Avg. volume 604,821
50-day MA $0.88 Dividend yield N/A
200-day MA $0.00 Market Cap 5.59M

Aclarion, Inc., (ACON) Company Bio


Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.


ACON Latest News Stream


Event/Time News Detail
Loading, please wait...

ACON Latest Social Stream


Loading social stream, please wait...

View Full ACON Social Stream

Latest ACON News From Around the Web

Below are the latest news stories about ACLARION INC that investors may wish to consider to help them evaluate ACON as an investment opportunity.

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option. Broomfield, CO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a health

Yahoo | December 1, 2022

Aclarion, Inc. (ACON) Gets a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Aclarion, Inc. (ACON - Research Report) yesterday and set a price target of $3.00. The company's shares opened today at $0.95.Vendetti covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, ReShape Lifesciences, and Venus Concept. According to TipRanks, Vendetti has an average return of -4.1% and a 32.47% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aclarion, Inc. with a $3.00 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $4.05 and a one-year low of $0.77. Currently, Aclarion, Inc.

Howard Kim on TipRanks | November 16, 2022

Aclarion Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Aclarion ( NASDAQ:ACON ) Third Quarter 2022 Results Key Financial Results Net loss: US$1.63m (loss widened by 90% from...

Yahoo | November 16, 2022

Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV

/ Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles.

Yahoo | October 25, 2022

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.

Yahoo | October 24, 2022

Read More 'ACON' Stories Here

ACON Price Returns

1-mo -26.53%
3-mo -41.46%
6-mo -28.36%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7005 seconds.